24 December 2017

TIKOMED CEO WILL BE MODERATING THE ”EVOLVING BIOPHARMA BOARDS” AT THE EAST/WEST CEO MEETING PRECEEDING JPMORGAN HEALTH CONFERENCE

Adam Bruce, CEO of TikoMed will be moderating the ”Evolving Biopharma Boards” panel discussion at the East/West CEO meeting preceeding J.P. Morgan Healthcare Conference
Panelists will include the below seasoned Biopharma leaders:
Martin Babler, CEO, Principia Biopharma; William Heiden, President & CEO, AMAG Pharmaceuticals; Catherine Sohn, Chairman, BioEclipse Therapeutics
Moderator: Adam Bruce, CEO, TikoMed
Adam Bruce, says: I am deeply honored to lead the panel for such an important subject. In the pharma world it is of absolute essence to have an aligned chain of competence, starting with owners,followed by the board and finally management. Given the phases of pharma development, it is in my opinion essential,to balance an evolution with continuity. I am excited to hear the panelists thoughts and experiences on the subject.
East/West CEO is a networking forum for industry CEOs and decision makers in the life sciences. Attendees gain insights from presentations and discussion panels featuring CEOs from several of the world’s leading biopharmaceutical companies. Healthcare investors also attend.
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

5 July 2018
Tikomed granted permission for clinical trial in ALS by the Swedish Medical Product Agency and Ethical Review Board.
Viken, May 28th, 2018 TikoMed, a specialty pharmaceutical company focused on developing therapeutics for treating…
Read More
5 July 2018
ILB – A game changer in Glaucoma
Viken, May 22nd, 2018 TikoMed, a specialty pharmaceutical company that focuses on developing therapeutics for…
Read More
5 June 2018
Anders Kristensson appointed CEO of TikoMed
Viken – 18th June 2018 TikoMed, a privately-held biopharmaceutical company today announced the appointment of…
Read More
SEE MORE